Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
نویسندگان
چکیده
منابع مشابه
Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
BACKGROUND Patients having chronic schizophrenia with frequent relapses and hospitalizations represent a great challenge, both clinically and financially. Risperidone long-acting injection (RIS-LAI) has been the main LAI atypical antipsychotic treatment in Greece. Paliperidone palmitate (PP-LAI) has recently been approved. It is dosed monthly, as opposed to biweekly for RIS-LAI, but such advant...
متن کاملPM394. The outcome of paliperidone palmitate in schizophrenia
Objective: This study is to evaluate the efficacy, functional improvements, and insight improvements in schizophrenic patients with long-acting injectable paliperidone palmitate (PP) treatment. Method: This is a 12-month, open-label, study from Taiwan, included 13 schizophrenic patients, between 17 and 72 years of age. Treatment response was assessed by Positive and Negative Syndrome Scale (PAN...
متن کاملPaliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia
OBJECTIVE Relapse and acute exacerbation are common in schizophrenia and may impact treatment response and outcome. Evidence is conflicting in respect to superiority of long-acting injectable antipsychotic therapies versus oral antipsychotics in relapse prevention. This randomized controlled study assessed the efficacy of paliperidone palmitate versus oral antipsychotics for relapse prevention....
متن کاملManic Symptoms during a Switch from Paliperidone ER to Paliperidone Palmitate in a Patient with Schizophrenia
Some antipsychotic drugs have treatment efficacy for mania and bipolar disorder. However, these drugs may rarely cause manic symptoms in some schizophrenic patients. We hereby report a 22-year-old female patient with schizophrenia who experienced a manic episode during a switch from paliperidone ER to paliperidone palmitate. This case is an important reminder that an abrupt switch from oral pal...
متن کاملPharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis
Schizophrenia presents a substantial clinical and economic burden to the health-care system. In QUAlity of LIfe with AbiliFY Maintena (QUALIFY), a randomized head-to-head study of aripiprazole once-monthly 400 mg (AOM 400) compared with paliperidone palmitate (PP; 78-234 mg/mo), AOM 400 demonstrated greater improvement in health-related quality of life and functioning in patients with stable sc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of General Psychiatry
سال: 2012
ISSN: 1744-859X
DOI: 10.1186/1744-859x-11-18